Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Imugene Limited ( (AU:IMU) ) has provided an update.
Imugene Limited announced the application for quotation of 901,615 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move signifies an important step in expanding the company’s financial resources and market presence, potentially enhancing its operational capacity and strategic positioning within the biotech industry.
More about Imugene Limited
Imugene Limited is a biotechnology company that operates in the pharmaceutical industry. It is primarily focused on developing and commercializing a range of innovative immunotherapies that aim to activate the immune system of cancer patients to treat and eradicate tumors.
YTD Price Performance: 30.0%
Average Trading Volume: 163,879
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $177.7M
For a thorough assessment of IMU stock, go to TipRanks’ Stock Analysis page.
